Island Pharmaceuticals Ltd
AASX:ILA0.32
AUD
-0.02
(-5.88%)
Island Pharmaceuticals Ltd
ASX:ILA
(Australian Securities Exchange)
Recent
price
0.32
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.- Similar Companies
- Business
- Island Pharmaceuticals Limited (ASX:ILA) is a clinical-stage pharmaceutical company focused on developing and commercializing innovative treatments for infectious diseases and reproductive health. The company offers a pipeline of product candidates including IXP1603, a long-acting tenofovir alafenamide formulation for HIV pre-exposure prophylaxis; BUL-001, a reformulated misoprostol for reproductive health indications such as labour induction and postpartum hemorrhage prevention; and other antiviral and antimicrobial therapies targeting unmet needs in global health. Island's products emphasize reformulation technologies to improve patient compliance, efficacy, and accessibility, particularly in low- and middle-income countries. Founded in 2019 and headquartered in Sydney, Australia, the company operates primarily in Australia with clinical trials and partnerships extending to the United States, Europe, and Asia-Pacific regions. In late 2024, Island announced a strategic collaboration with a leading global health organization to advance BUL-001 into Phase III trials, alongside securing a A$10 million funding round to support pipeline expansion and manufacturing scale-up.
Company News
Island Pharmaceuticals inks US Army research deal to advance Marburg antiviral program